NCT01874145View on ClinicalTrials.gov

Safety and Tolerability of Glatiramer Acetate

PHASE3CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

GA 20 mg/mL

Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.

DRUG

GA 40 mg/mL

Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.

Trial Locations (35)

Unknown

Teva Investigational Site 10706, Cullman

Teva Investigational Site 10719, Gilbert

Teva Investigational Site 10720, Phoenix

Teva Investigational Site 10727, Fresno

Teva Investigational Site 10731, Long Beach

Teva Investigational Site 10735, Newport Beach

Teva Investigational Site 10712, Oceanside

Teva Investigational Site 10708, Centennial

Teva Investigational Site 10715, Maitland

Teva Investigational Site 10718, Pompano Beach

Teva Investigational Site 10709, St. Petersburg

Teva Investigational Site 10707, Tampa

Teva Investigational Site 10711, Tampa

Teva Investigational Site 10710, Northbrook

Teva Investigational Site 10734, Indianapolis

Teva Investigational Site 10732, Baltimore

Teva Investigational Site 10726, Great Falls

Teva Investigational Site 10702, Henderson

Teva Investigational Site 10717, Patchogue

Teva Investigational Site 10723, Plainview

Teva Investigational Site 10716, Charlotte

Teva Investigational Site 10724, Raleigh

Teva Investigational Site 10721, Winston-Salem

Teva Investigational Site 10733, Bellevue

Teva Investigational Site 10703, Columbus

Teva Investigational Site 10714, Dayton

Teva Investigational Site 10704, Uniontown

Teva Investigational Site 10725, East Providence

Teva Investigational Site 10736, Cordova

Teva Investigational Site 10701, Franklin

Teva Investigational Site 10728, Nashville

Teva Investigational Site 10729, Mansfield

Teva Investigational Site 10722, Round Rock

Teva Investigational Site 10699, Salt Lake City

Teva Investigational Site 10700, Roanoke

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01874145 - Safety and Tolerability of Glatiramer Acetate | Biotech Hunter | Biotech Hunter